To understand the role of gut microbes in host health, it is imperative to probe their genetic potential, expression, and ecological status. The current high-throughput sequencing revolution, in addition to advances in mass spectrometry-based proteomics, have recently enabled deep access to these complex environments, and are revealing great insights into the roles of the gastrointestinal (GI) microbiota in host physiology and health. This review discusses examples of how the integration of cutting-edge 'meta-omics' technologies are providing new knowledge about the relationships between host health status in mammals, with a focus on human hosts, and the microbes inhabiting the GI tract. In addition, we address some promises that these techniques hold for future therapeutics and diagnostic applications.
The Earth Microbiome Project aims to include thousands of samples from mammalian hosts that will be compared to other microbial communities from diverse habitats on Earth, ranging from marine to soil, thus enabling elucidation of patterns leading to host-associated life styles.
Lessons learned from metagenomic surveys of mammalian gastrointestinal environments.
The microbiomics studies discussed above provide information about species identities, but not about the functional potential of members of the gut microbial community. By contrast, metagenomic sequencing of total community DNA provides information about both the phylogenetic representation, as well as functional genes [4,5,23-25**]. By comparison of several existing metagenome databases, we can clearly see that the mammalian gut metagenomes 7 are different from those inhabiting other environments ( Figure 1) . The gut represents a unique functional environment endowed with a cache of genes encoding processes required for food digestion and host immunity. Consistent host-mediated selective pressures compounded with, a microbially dense, high nutrient environment has most likely created a hotspot for microbial evolution and adaptation in the mammalian gut that is distinct from free-living environments.
Metagenomic studies of mammalian gastrointestinal environments have largely focused on gene-centric approaches to unveil functionality encoded by the microbiome, as a result of its vast phylogenetic and functional repertoires. Comparative metagenomics studies have provided insights into inter-individual host differences, as well as differences between different In another recent report from the MetaHIT consortium, metagenomic mining of the human gut revealed three distinctly robust "enterotypes" that spanned across geography, age, gender, and disease [27**] ( Figure 2 ). The three enterotypes were strongly driven by species composition (Bacteroides, Prevotella, and Blautia/unclassified Lachnospiraceae, respectively).
The finding that the human gut microbiota can be classified into different enterotypes could have important ramifications for predicting individual responses to therapeutics.
While next-generation sequencing technologies are generating gigabase and approaching terabase scale metagenome datasets, new challenges have arisen. For example, it remains challenging to tie novel functional capacities to specific microorganisms. This challenge should be facilitated by continued generation of whole genomes from metagenomic data, in addition to single cell genome sequencing, and sequencing of more cultured isolates. Another challenge is the increased amount of data that is represented by increasingly shorter read lengths, often with questionable sequence quality. This is demanding increasingly complex computation, data storage, and handling requirements. Additionally, more sophisticated algorithms are necessary to help improve sequence assemblies in complex microbial communities such as the gut.
Specifically this problem must be solved to facilitate screening of functional genes in their genomic context (i.e. operons) and for application of some of the other "omics" technologies, such as metaproteomics that relies on accurately assembled and annotated metagenome databases for peptide predictions as described below.
Other "Omics": Metatranscriptomics, Metaproteomics, and Metametabolomics: Activity

Hallmarks
Although metagenomics provides information about functional gene content in the gut, it is not known whether the genes are actively expressed and have any functional role in a given sample. When extracting total DNA, it is not possible to know if it originated from intact, viable cells, or not, and is therefore not an ideal proxy for assessing functions carried out by the community at a specific point in time. In order to obtain information about active functions, it is necessary to look at the expression profile (metatranscriptomics) or the protein products (metaproteomics). These two technologies are still technically demanding and have only recently begun to be applied for the study of microbial communities.
Sequencing of RNA has recently been used to obtain information about gene expression
in the gut under different conditions. For example, metatranscriptomics was used to compare cecal contents from piglets fed with sow's milk compared to artificial formula, with the finding that several pathways for amino acid metabolism and oxidative stress varied in expression profiles between the two groups [29] . In another study a metatranscriptome approach was used to determine expression of genes involved in carbohydrate metabolism in the gut [30], with the finding that different genes were specifically expressed in different individuals at any given time.
Metatranscriptomics of a healthy human twin pair revealed that the gut had a high representation of expressed genes for carbohydrate metabolism, energy production and synthesis of cellular components [31]. In addition, small RNAs were expressed in the gut, which have important roles as regulatory elements involved in bacterial physiology and pathogenicity [31] .
While metatranscriptomics is probing the expression dynamics associated with complex microbial communities, this new technology must deal with the inherent biases associated with the need for subtraction of ribosomal RNA (rRNA) that is normally the dominant RNA species extracted, usually comprising over 90% of the total RNA. This problem may be overcome in the future by deep sequencing of total RNA, including rRNA, since current depth of coverage would still be sufficient for obtaining considerable mRNA transcripts (i.e. one lane of Illumina HiSeq generates approximately 50 Gb of sequence). If 90% of that is rRNA, that still leaves 5 Gb of other RNA, including billions of transcript reads). In addition, RNA is simply more difficult to prepare and preserve compared to DNA due to its chemical nature. The next step in the "omics" information pipeline is to examine expressed and translated protein products, using a metaproteomics approach. Use of shotgun metaproteomics for analysis of the gut microbiota was first demonstrated for a pair of healthy twins [32] . Briefly the microbial community was enriched from feces by density centrifugation and the entire metaproteome, without selection, was denatured and digested into peptides with trypsin. The peptides were injected onto a two-dimensional liquid chromatography (LC) system coupled with a rapid scanning high-resolution mass spectrometer (MS) and the resulting high accuracy peptide masses were searched against a database containing gut metagenomes and bacterial reference genomes. By comparing clusters of orthologous groups (COGs) of the metaproteomes to metagenomes, it was apparent that the metaproteomes had a higher representation of proteins in COGs for translation, carbohydrate metabolism and energy production than was predicted from the metagenomes [32] . Similar to the metatranscriptome study mentioned above [31], these data highlighted key functions that were more active in the human gut that could not be predicted from metagenomes.
Although the use of this shotgun proteomics approach based on high performance mass spectrometry (MS) was a significant step forward, it also demonstrated that large technological advances are still needed. The most pressing current bottleneck for metaproteomics of complex environments, such as the gut, is the incompleteness and poor validation of the predicted protein databases used for peptide matching to the millions of tandem mass spectra (MS/MS) obtained in a typical study. The best case scenario is to have matched metagenome databases from the same samples to increase the number of proteins identified [33, 34] . Also, we can now take advantage of the increase in available human gut microbiome isolate genomes being produced through the NIH Human Microbiome Project to augment databases with well annotated genes by decreasing production of its glycan-degrading enzymes. This study is a good example, albeit a simplified model, of using a systems biology approach to better understand niche specialization and functional redundancy of representatives of two common gut bacteria and is currently being expanded to more complex but controlled systems.
The final proof that metabolic processes have occurred in the gut is evident by examination of metabolic products. The field of (meta)metabolomics, also called metabonomics
[37] has yielded interesting insights into gut function. A comparison of metabolites in fecal extracts of humans, mice and rats by NMR spectroscopy revealed that while some metabolites were common to all species, such as short chain fatty acids, each host species had a unique metabolic profile [38] . Recent research has also demonstrated the large impact the gut microbiome has on mammalian blood metabolites, suggesting a major interplay between bacterial and mammalian metabolism [39*].When the metabolic profiles of different portions of mouse intestines were compared, the biochemical composition of each topographical intestinal region possessed a specific metabolic profile [40] . The metabolomics field is currently in need of transformational advances to more easily handle the plethora of small molecule metabolites produced by the microbiota and more complete metabolite databases to enable accurate identification of metabolites.
Omics insights to the role of the gut microbiota in health
Impact of Diet
Recent "omics" studies have emphasized the importance of diet on shaping the structure of the mammalian gut microbiota. A comparative metagenomic survey of 33 mammalian species, illustrated how the gut microbiota adapts to diet, and how these adaptation events span across different mammalian lineages, supporting the theory of convergence of microbial communities within gastrointestinal systems [41*]. Comparative studies of the cow rumen and termite hindgut microbiome, showed fundamental differences in glycoside hydrolase and cellulosome functional genes, most likely due to the different diets of the respective hosts as their resident microbes coevolved to digest different plant cell wall types [5] . In another recent comparative metagenomics study, similar functional gene profiles were found among swine gut, chicken cecum and cow rumen. This finding may seem counterintuitive considering the vast differences in gut anatomy and physiology of these hosts, but in this case, the similarities were attributed to similar animal husbandry practices [26] . In a metagenomic study of Japanese individuals, a gene encoding a microbial β-porphyranase from a marine microbe, Zobellia galactanivorans, was detected in DNA sequences from the gut microbe, Bacteroides plebeius [42*]. This finding suggests that these novel carbohydrate active enzymes were acquired by horizontal gene transfer in the gut metagenome of Japanese individuals that include seaweed in their diet. Furthermore, in a controlled feeding study, gut microbial enterotypes were strongly associated with diet, with Bacteroides correlating to diets high in protein and animal fat, while diets high in carbohydrates were associated with a prevalence of Prevotella [43] . 
Impact of Disease
Several different studies of inflammatory bowel disease (IBD) have demonstrated a gut microbiota that is disturbed compared to a normal healthy state. This "dysbiosis" of the gut microbiota has been highlighted in studies of individuals with the specific IBD disease, Crohn's Disease (CD), in particular those individuals with inflammation in the small intestine, or ileum.
These individuals have a lower fecal microbial diversity in general, as well as a reduction in several members of the Firmicutes phylum [10,13,46]. One example of a particular microbe that was less abundant in ileal CD was Faecalibacterium prausnitzii, a bacterium that is considered to be beneficial due to its action as a producer of butyrate, a substrate for gut epithelial cells ( Figure 3 ). In addition, to shifts in the microbial community, there were thousands of metabolites that differed in amounts in fecal water extracts of healthy individuals and those with Crohn's disease when using a metabolomics screening approach [12] . Some other diseases, such as necrotizing enterocolitis in infants, have also been correlated to dramatic perturbations in the fecal microbiota; in this case comprising only members of the Proteobacteria and Firmicutes [47] . Further research is necessary to untangle whether the microbiota has a causative role in disease, or whether dysbiosis is a by-product of the disease
Promise of "Omics" for Diagnostic and Therapeutic Biotechnological applications
These advances in "omics" approaches are promising for several biotechnological applications, including biomarker discovery for novel diagnostics and new drug targets, as well as therapeutic strategies. The importance of the gut microbiota for therapeutic applications was dramatically revealed in a study using bacteriotherapy by way of fecal transplantation, to successfully treat Clostridium difficile-associated disease and reestablish the normal colonic microbiota [11**]. Additionally, use of beneficial bacteria as probiotics is a promising therapy to improve symptoms of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease [48, 49] . Exploiting the gut metagenome for the development of novel therapeutics, including antimicrobial peptides, immunoregulatory molecules and stress tolerance genes is another emerging area of research with hopes to increase the technological and physiological efficacy of probiotic bacterial strains. Additionally, advances in genomics, transcriptomics, and metabolomics are facilitating a deep understanding of the modes of action of specific probiotics. Each taxa, protein, or metabolite was plotted as its difference in relative abundance. Blue and orange taxa, proteins, or metabolites have higher relative abundance in Patient 6A and Patient 6B, respectively. For visualization purposes, taxa with relative abundances greater that 30%, metabolites greater than 2%, and proteins greater than 0.6% were removed. (D) Network of KEGG pathways plotted as the log fold change difference in expression of pathways from patient 6A to patient 6B. Red=higher pathway expression in patient 6B; Green= higher pathway expression in patient 6A; brown= more equivalent pathway expression in 6A and 6B. Pathway 20 nodes are sized by the average pathway expression for both patients. Grey nodes denote pathways not captured in the metaproteomes. 
